Skip to main content
Clinical Trials/DRKS00027130
DRKS00027130RecruitingPhase 3

Expectation management and open label placebo: Novel approaches to improve treatment outcome of pain and gluten intolerance in patients with fibromyalgia

niversitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Anästhesiologie, Schmerzmedizin und Schmerzpsychologie0 sites100 target enrollmentStarted: March 17, 2022Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Sponsor
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomized controlled study
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to one (—)
Sex
All

Inclusion Criteria

  • Diagnosis of fibromyalgia syndrome;
  • minimum age 18 years
  • sufficient knowledge of the German language

Exclusion Criteria

  • Diagnosis of gluten-sensitive enteropathy or wheat allergy, or abnormal blood results during screening;
  • Severe acute or chronic mental health condition (e.g., psychosis, severe depression);
  • Presence of active chronic gastrointestinal disease requiring acute or other treatment;
  • Presence of other active pain disorders with a dominant role in pain symptoms, requiring acute or other treatment;
  • Current condition of pregnancy or breast-feeding;
  • Current treatment with anti-inflammatory medication (which might influence the experimental serum parameters)
  • Patients with galactose-intolerance, lactase deficiency or glucose-galactose-malabsorption
  • Allergy against ingredients of porridge (Nestle BEBA Sinlac, rice flakes, fructose)

Investigators

Sponsor
niversitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Anästhesiologie, Schmerzmedizin und Schmerzpsychologie

Similar Trials

Expectation management and open label... | Clinical Trial